Up to 98.5% Shandong 40 varieties with volume procurement results outflow

40 varieties officially opened, the price of new lows ...official opening of tenders, price reduction near the countrytoday (November 25), Shandong Province, the first batch of 40 drugs with volume purchase officially opened, according to Shandong with the volume of the official website live public content and industry insiders revealed: The average decline in Shandong collection reached more than 50%, there are nearly ten product regulations fell by 90%, and the largest decline for Shandong Yuxin Pharmaceutical Co., Ltd. injection with Lansorazole injection sterile powder 30mg1 bottle / bottle, reached 98.58 percent.October 11, Shandong Province official Xuan: 40 varieties of belt procurement began to implement. According to Cypress blue combing, aspirin, nitrobenzene, mettorol, fluorocarbon, omeprazole, reberazine, compound glyphosate, lansolazi, left ammonia chloride equal common varieties are in Shandong this collection range. Of the 40 varieties, 27 were injectable, 13 were oral, and the proportion of injection forms was more than two-thirds, with the second round of national collection mainly in oral dosage forms, the difference was obvious.It is reported that the centralized volume of procurement, including the treatment of cardiovascular, tumor and other diseases of 40 drugs, involving a market share of 5 billion yuan. There are 368 enterprises involved in Shandong collection, involving 1075 products. Shandong is currently the country's provinces with a single organization to purchase the largest number of drug varieties, involving the largest amount of provinces.That morning should participate in the field encryption quotation of 321 enterprises, 585 products. Declassified the number of successful enterprises 320, the number of products 584. Among them, the first review group of 24 products, the second review group of 560 products.Official reports show that since 2019, Shandong has implemented three batches, 112 kinds of national drug collection results, drug prices fell by an average of more than 50%, the highest reduction of more than 90%, can save the burden of drug costs 2.754 billion yuan per year, the reform of the people has a remarkable effect. This provincial group with volume procurement, will further benefit the insured masses.

two review groups, the price is at a record lowFrom the current industry spread in Shandong Province with the volume of procurement results, enterprises reported a larger price reduction, many products prices hit a new low.Fengyun drug talk analysis, such as Parexib sodium, anti-oral, anti-vitolaze injections such as the fourth batch of popular products, if this shortlisted for the fourth batch, the price is basically in this benchmark up and down. In addition, the prices of several products have been hit directly to the end, in other words, in other provinces with the volume of procurement, other enterprises on the current price is also difficult to participate.This is basically in line with the country's expectations of regional volume procurement - the selection of national varieties of the bottom line is too consistent evaluation, if the product has not been consistent evaluation, can first be carried out by the local volume procurement, if with the increase of the evaluation of products, gradually meet the conditions of the national belt procurement, may be transferred to the national volume procurement scope, at this time the local collection of procurement prices, will automatically become the National Health Insurance Bureau to find out the true cost of enterprises, to help further understand the true cost of enterprises.Shandong Province this time will be the product evaluation group, over-protection period of patented drugs, consistent evaluation of the evaluation of the preparation, through the quality and efficacy of consistent evaluation of generic drugs, according to the new registration classification of chemicals approved imitation drugs, included in the "China Listed Drugs Listed List" of drugs, as well as China's domestic production of drugs certified by the United States, the European Union (Germany, France), the United Kingdom, Canada, Australia, Japan as the first review group;To some extent, Shandong Province's pharmaceutical resources in the forefront of the country, the original research drugs and over-evaluation of drug groups, to avoid its and domestic generic drugs to carry out bottomless price killing, but also to a certain extent also limited its potential for price reduction - overall, the first level of price decline in about 26%, far lower than the average decline of the second level.In addition, the above-mentioned evaluation rules balance economic and technical points with quotations - if the economic and technical points are ideal and the price is reasonable, there is a good chance that they will be shortlisted; This is Shandong Province's innovation on the improvement and upgrading of the double envelope system, but also learn from other regions.

varieties are there, price dive?According to industry news, many enterprises reported a more than 90% drop in ultra-low prices, Fujian Province, Dongli Express Pharmaceuticals injection cytophosphocholine sodium(0.25g) fell by 96.99%;   For example, the fourth batch of popular varieties of injection with Parexib sodium, Hunan Cylon Pharmaceuticals reported a price of 3.33 yuan / branch, a 93% decrease, although it did not pass the consistent evaluation, it is difficult to obtain the fourth collection tickets, but through a significant price reduction to obtain the second evaluation group of Shandong collection of the winning opportunity.   In addition, as a provincial and local volume purchase of regular customers, there are 2 proton pump inhibitors (PPI) price dive significantly.   According to insight data, in terms of the injection of sodium omeprazole this variety, 62 enterprises meet the declaration conditions, Suzhou second leaf injection sterile powder dosage form (40mg) reported 0.84 yuan / branch (the original hanging network price of 10.03 yuan / branch), a decrease of 91%.   Injection of Esomerazo sodium has 24 enterprises to participate in the collection, Chongqing Dikang, Shandong Luoxin, YichangDong Sunshine decline of more than 80%, Yichang East Sunshine 20mg quoted 4.2 yuan / branch, down 88%;   In recent years, china's public medical institutions end-injection sales of Esomeprazole sodium increased year by year, in 2019 exceeded 3 billion yuan, an increase of 17% year-on-year.   In addition, the oral regular release dosage form (40mg) and the pythonazole injection (40mg) are also reported by enterprises 0.67 yuan / branch, 2.71 yuan / 7 pieces / box, 3.8 yuan / 7 pieces / box price.   Sales of sodium vitolazole for injection at china's public medical facilities peaked at nearly 9 billion yuan and have continued to decline since then, but will remain a heavy-weight product with annual sales of more than 5 billion yuan in 2019, according to Mienet data.   In 2019, china's public medical institutions terminal PPI injection market size of more than 20 billion yuan. At present, 7 PPI injections have enterprise layout consistency evaluation, of which 6 declared enterprises up to 3 and above. Since this year, Jiangxi, Qinghai, Fujian, Fuyang, Wuhan and other provinces and cities announced the results of the collection, Osaikang, Dongsai sunshine medicine, Zhengda Qing, Qilu and other PPI injection price reduction market.   The decline in the volume of procurement in Shandong Province is obvious, and there are many varieties for the fourth batch of popular varieties, or will bring price reference significance to the national harvest and other provinces. (Cypress Blue)